Oramed Historical Balance Sheet

ORMP Stock

USD 2.37 0.02 0.85%

Trend analysis of Oramed Pharmaceuticals balance sheet accounts such as Other Stockholder Equity of 379.7 M provides information on Oramed Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Oramed Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Oramed Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Oramed Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Oramed Pharmaceuticals is a good buy for the upcoming year.

Oramed Pharmaceuticals Inventory

13,735.04

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.

About Oramed Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Oramed Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Oramed Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Oramed Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Oramed currently owns. An asset can also be divided into two categories, current and non-current.

Oramed Pharmaceuticals Balance Sheet Chart

At this time, Oramed Pharmaceuticals' Net Debt is relatively stable compared to the past year. As of 11/27/2024, Accounts Payable is likely to grow to about 822.2 K, while Non Current Liabilities Total is likely to drop slightly above 4.2 M.

Common Stock Shares Outstanding Other Stockholder Equity Total Liab Current Deferred Revenue Short Long Term Debt

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Most accounts from Oramed Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Oramed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.At this time, Oramed Pharmaceuticals' Net Debt is relatively stable compared to the past year. As of 11/27/2024, Accounts Payable is likely to grow to about 822.2 K, while Non Current Liabilities Total is likely to drop slightly above 4.2 M.

	2021	2022	2023	2024 (projected)
Total Liabilities	11.5M	10.5M	57.7M	60.5M
Other Stockholder Equity	230.2M	314.4M	361.6M	379.7M

Total Liab Other Stockholder Equity

Oramed Pharmaceuticals balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Net Debt	Accounts Payable	Cash	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Current Assets	Short Long Term Debt Total	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Short Term Debt	Short Term Investments	Net Receivables	Inventory	Current Deferred Revenue	Capital Lease Obligations
Other Current Liab		-0.2	-0.46	0.32	-0.37	-0.39	-0.08	-0.39	-0.39	0.29	-0.52	-0.58	-0.41	0.43	-0.28	-0.42	-0.45	-0.44	-0.23	-0.58	-0.4	-0.25	0.02	0.19	0.05	-0.49
Total Current Liabilities	-0.2		0.79	-0.7	0.78	0.82	0.96	0.79	0.87	0.63	-0.02	0.03	0.84	0.03	0.0	0.8	0.82	0.74	0.92	-0.05	0.57	0.89	-0.18	-0.77	0.27	0.59
Total Stockholder Equity	-0.46	0.79		-0.93	0.97	0.99	0.77	0.97	0.99	0.1	0.48	0.53	0.99	0.03	0.29	0.99	0.96	0.98	0.8	0.28	0.69	0.91	-0.05	-0.72	0.33	0.94
Retained Earnings	0.32	-0.7	-0.93		-0.99	-0.97	-0.74	-0.98	-0.93	-0.02	-0.56	-0.54	-0.94	-0.28	-0.37	-0.95	-0.84	-0.9	-0.71	-0.23	-0.54	-0.86	-0.03	0.74	-0.57	-0.87
Common Stock Shares Outstanding	-0.37	0.78	0.97	-0.99		0.99	0.79	0.99	0.97	0.1	0.51	0.51	0.98	0.18	0.32	0.98	0.9	0.95	0.77	0.22	0.6	0.91	-0.01	-0.77	0.49	0.9
Other Stockholder Equity	-0.39	0.82	0.99	-0.97	0.99		0.82	0.99	0.99	0.15	0.46	0.49	0.99	0.13	0.3	0.99	0.94	0.96	0.82	0.22	0.64	0.93	-0.04	-0.77	0.43	0.91
Total Liab	-0.08	0.96	0.77	-0.74	0.79	0.82		0.8	0.86	0.59	0.07	0.04	0.82	0.3	0.0	0.78	0.76	0.69	0.93	-0.05	0.48	0.87	-0.11	-0.81	0.47	0.55
Common Stock	-0.39	0.79	0.97	-0.98	0.99	0.99	0.8		0.97	0.08	0.51	0.55	0.97	0.17	0.32	0.97	0.89	0.93	0.81	0.28	0.56	0.88	-0.03	-0.78	0.51	0.88
Total Assets	-0.39	0.87	0.99	-0.93	0.97	0.99	0.86	0.97		0.22	0.41	0.44	0.99	0.1	0.24	0.99	0.96	0.95	0.87	0.21	0.67	0.94	-0.06	-0.78	0.38	0.89
Net Debt	0.29	0.63	0.1	-0.02	0.1	0.15	0.59	0.08	0.22		-0.64	-0.76	0.21	-0.06	-0.37	0.15	0.23	0.09	0.4	-0.7	0.18	0.46	-0.22	-0.37	-0.18	-0.1
Accounts Payable	-0.52	-0.02	0.48	-0.56	0.51	0.46	0.07	0.51	0.41	-0.64		0.78	0.41	0.33	0.34	0.46	0.3	0.43	0.18	0.63	0.1	0.21	0.22	-0.36	0.51	0.55
Cash	-0.58	0.03	0.53	-0.54	0.51	0.49	0.04	0.55	0.44	-0.76	0.78		0.44	0.04	0.48	0.48	0.41	0.51	0.25	0.87	0.27	0.15	0.11	-0.15	0.39	0.63
Cash And Short Term Investments	-0.41	0.84	0.99	-0.94	0.98	0.99	0.82	0.97	0.99	0.21	0.41	0.44		0.06	0.27	1.0	0.97	0.98	0.81	0.17	0.69	0.95	-0.07	-0.75	0.34	0.92
Non Current Liabilities Total	0.43	0.03	0.03	-0.28	0.18	0.13	0.3	0.17	0.1	-0.06	0.33	0.04	0.06		-0.01	0.07	-0.1	-0.05	0.17	-0.01	-0.22	0.06	0.24	-0.29	0.82	-0.05
Other Current Assets	-0.28	0.0	0.29	-0.37	0.32	0.3	0.0	0.32	0.24	-0.37	0.34	0.48	0.27	-0.01		0.3	0.24	0.35	0.0	0.31	0.08	0.14	0.37	0.11	0.18	0.42
Total Current Assets	-0.42	0.8	0.99	-0.95	0.98	0.99	0.78	0.97	0.99	0.15	0.46	0.48	1.0	0.07	0.3		0.96	0.98	0.78	0.19	0.68	0.94	-0.05	-0.73	0.35	0.94
Short Long Term Debt Total	-0.45	0.82	0.96	-0.84	0.9	0.94	0.76	0.89	0.96	0.23	0.3	0.41	0.97	-0.1	0.24	0.96		0.98	0.78	0.17	0.83	0.93	-0.09	-0.62	0.17	0.93
Property Plant And Equipment Net	-0.44	0.74	0.98	-0.9	0.95	0.96	0.69	0.93	0.95	0.09	0.43	0.51	0.98	-0.05	0.35	0.98	0.98		0.71	0.21	0.75	0.91	-0.06	-0.62	0.23	0.98
Non Current Assets Total	-0.23	0.92	0.8	-0.71	0.77	0.82	0.93	0.81	0.87	0.4	0.18	0.25	0.81	0.17	0.0	0.78	0.78	0.71		0.25	0.5	0.78	-0.1	-0.78	0.42	0.59
Non Currrent Assets Other	-0.58	-0.05	0.28	-0.23	0.22	0.22	-0.05	0.28	0.21	-0.7	0.63	0.87	0.17	-0.01	0.31	0.19	0.17	0.21	0.25		0.07	-0.12	0.1	-0.03	0.33	0.31
Short Term Debt	-0.4	0.57	0.69	-0.54	0.6	0.64	0.48	0.56	0.67	0.18	0.1	0.27	0.69	-0.22	0.08	0.68	0.83	0.75	0.5	0.07		0.68	0.07	-0.26	-0.06	0.73
Short Term Investments	-0.25	0.89	0.91	-0.86	0.91	0.93	0.87	0.88	0.94	0.46	0.21	0.15	0.95	0.06	0.14	0.94	0.93	0.91	0.78	-0.12	0.68		-0.1	-0.77	0.24	0.81
Net Receivables	0.02	-0.18	-0.05	-0.03	-0.01	-0.04	-0.11	-0.03	-0.06	-0.22	0.22	0.11	-0.07	0.24	0.37	-0.05	-0.09	-0.06	-0.1	0.1	0.07	-0.1		0.08	0.2	-0.02
Inventory	0.19	-0.77	-0.72	0.74	-0.77	-0.77	-0.81	-0.78	-0.78	-0.37	-0.36	-0.15	-0.75	-0.29	0.11	-0.73	-0.62	-0.62	-0.78	-0.03	-0.26	-0.77	0.08		-0.5	-0.51
Current Deferred Revenue	0.05	0.27	0.33	-0.57	0.49	0.43	0.47	0.51	0.38	-0.18	0.51	0.39	0.34	0.82	0.18	0.35	0.17	0.23	0.42	0.33	-0.06	0.24	0.2	-0.5		0.19
Capital Lease Obligations	-0.49	0.59	0.94	-0.87	0.9	0.91	0.55	0.88	0.89	-0.1	0.55	0.63	0.92	-0.05	0.42	0.94	0.93	0.98	0.59	0.31	0.73	0.81	-0.02	-0.51	0.19

Click cells to compare fundamentals

Oramed Pharmaceuticals Account Relationship Matchups

Oramed Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	(69K)	601K	(1.4M)	(191K)	(171.9K)	(163.3K)
Total Current Liabilities	5.3M	4.5M	6.7M	5.7M	53.2M	55.9M
Total Stockholder Equity	19.4M	32.9M	115.8M	151.8M	163.8M	172.0M
Retained Earnings	(81.1M)	(92.6M)	(114.9M)	(163.1M)	(157.6M)	(149.7M)
Common Stock Shares Outstanding	17.5M	20.5M	28.5M	39.0M	40.3M	42.4M
Other Stockholder Equity	100.3M	125.2M	230.2M	314.4M	361.6M	379.7M
Total Liab	15.3M	11.8M	11.5M	10.5M	57.7M	60.5M
Common Stock	208K	284K	424K	476K	547.4K	574.8K
Total Assets	34.7M	44.6M	128.0M	161.6M	220.6M	231.6M
Net Debt	(3.3M)	(19.2M)	(76.7M)	(39.6M)	42.0M	44.1M
Accounts Payable	1.3M	594K	2.6M	2.2M	551K	822.2K
Cash	3.3M	19.3M	77.2M	40.5M	9.1M	10.6M
Cash And Short Term Investments	32.3M	39.9M	94.1M	155.7M	179.1M	188.0M
Liabilities And Stockholders Equity	34.7M	44.6M	128.0M	161.6M	185.9M	195.2M
Non Current Liabilities Total	10.0M	7.2M	4.8M	4.7M	4.4M	4.2M
Other Current Assets	1.0M	611K	1.2M	1.4M	537K	536.1K
Total Current Assets	33.3M	40.5M	95.3M	157.1M	162.6M	170.7M
Property Plant And Equipment Net	24K	174K	932K	1.8M	1.6M	1.6M
Non Current Assets Total	1.3M	4.1M	32.7M	4.5M	58.0M	60.9M
Short Term Investments	29.0M	20.6M	16.9M	115.3M	153.0M	160.6M

Pair Trading with Oramed Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Oramed Stock

0.61	NAMS	NewAmsterdam Pharma	Pair Corr
0.54	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.42	GILD	Gilead Sciences	Pair Corr
0.42	PMVP	Pmv Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.

The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Oramed Stock Analysis

When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oramed Historical Balance Sheet

Oramed Pharmaceuticals Inventory

13,735.04

About Oramed Balance Sheet Analysis

Oramed Pharmaceuticals Balance Sheet Chart

Common Stock Shares Outstanding

Total Liab

Current Deferred Revenue

Short Long Term Debt

Oramed Pharmaceuticals balance sheet Correlations

Oramed Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oramed Pharmaceuticals balance sheet Accounts

Pair Trading with Oramed Pharmaceuticals

Moving against Oramed Stock

Additional Tools for Oramed Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Total Stockholder Equity
Total Assets	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Total Stockholder Equity
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding

Common Stock Shares Outstanding	- 0.99	Retained Earnings
Common Stock	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Total Current Assets	- 0.95	Retained Earnings
Cash And Short Term Investments	- 0.94	Retained Earnings
Total Assets	- 0.93	Retained Earnings